Routine cancer screening tests are not offered to everyone, and age limits are a common feature of many national screening programmes, including those in the UK. The National Health Service (NHS) currently offers screening for breast, bowel, and cervical cancers, each with specific age ranges. For example, breast cancer screening is routinely offered to women aged 50 to 71, while bowel cancer screening is offered to everyone aged 60 to 74. Cervical cancer screening is offered to women and people with a cervix aged 25 to 64.
The Rationale Behind Age Limits
The primary reason for age limits is based on a careful balance of risks and benefits. Screening tests are not perfect; they can produce false positives, leading to unnecessary anxiety and invasive follow-up procedures, or false negatives, providing false reassurance. Moreover, overdiagnosis—detecting cancers that would never have caused symptoms or harm—can lead to overtreatment, which carries its own physical and psychological side effects.
Age limits are set by expert committees that review scientific evidence on the effectiveness of screening in different age groups. For younger people, the risk of developing certain cancers is lower, and the potential harms of screening may outweigh the benefits. For older people, the risk may increase, but so do the chances of overdiagnosis and competing causes of death, making screening less beneficial.
Breast Cancer Screening
Breast cancer screening uses mammography to detect early signs of breast cancer. The NHS offers screening every three years for women aged 50 to 71. Studies have shown that screening reduces breast cancer mortality by about 20% in women invited for screening, but the benefit is smaller in younger women due to lower incidence and denser breast tissue, which can make mammograms harder to interpret. In older women, the risk of overdiagnosis increases, and the benefit in terms of life years gained may be limited.
Bowel Cancer Screening
Bowel cancer screening is offered to people aged 60 to 74 using a home testing kit (FIT) that detects hidden blood in stools. The age limit is based on evidence that the incidence of bowel cancer rises sharply after age 50 and peaks in the 70s. Screening has been shown to reduce bowel cancer deaths by about 25% in those who participate. However, in younger people, the risk is low, and false positives can lead to unnecessary colonoscopies. In older people, the risk of complications from follow-up procedures may outweigh the benefits.
Cervical Cancer Screening
Cervical cancer screening is offered to women and people with a cervix aged 25 to 64. The age limit is set because cervical cancer is rare in women under 25, and screening can lead to unnecessary treatment of abnormalities that would resolve on their own, potentially affecting fertility. After age 64, the risk of developing cervical cancer is low, especially for those who have been regularly screened and had normal results.
Exceptions and Individual Circumstances
While age limits apply to routine screening, individuals with a higher risk due to family history, genetic predisposition, or other factors may be offered screening outside these age ranges. For example, women with a strong family history of breast cancer may be offered mammograms or MRI scans from a younger age. Similarly, people with certain genetic conditions like Lynch syndrome may start bowel cancer screening earlier.
It is also important to note that age limits are not absolute cut-offs. The NHS advises that people over the screening age who are concerned about symptoms should still consult their GP, as they may be eligible for diagnostic tests. The key message is that screening is for asymptomatic individuals; anyone with symptoms should seek medical advice regardless of age.
Ongoing Research and Future Changes
Age limits are not static; they are regularly reviewed as new evidence emerges. For instance, there have been calls to extend breast cancer screening to women aged 40-49, based on trials showing a small reduction in mortality. However, this would also increase false positives and overdiagnosis. Similarly, some argue that bowel cancer screening should start at age 50, as is done in some other countries. The NHS is currently evaluating the evidence and may adjust age limits in the future.
In conclusion, age limits for routine cancer tests are based on a careful evaluation of the balance between benefits and harms. They aim to maximize the population benefit while minimizing unnecessary harm. Individuals who are concerned about their risk should discuss their options with a healthcare professional.
